Login to Your Account



J&J moves Genmab’s Daratumumab into phase III myeloma trial

By Cormac Sheridan
Staff Writer

Thursday, March 6, 2014
Janssen Biotech, Inc. is putting its foot on the gas in the development of Genmab A/S’s anti-CD38 multiple myeloma antibody daratumumab. Although it does not yet have any final phase II data in hand, it feels sufficiently emboldened by what it’s seen so far to move the drug into an extensive-phase pivotal program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription